Introduction
An estimated 60 million people in sub-Saharan African countries are at risk for human African trypanomiasis (HAT), especially poor and neglected populations living in remote areas (1, 2) . In west and central Africa where it is endemic, Trypanosoma brucei gambiense causes a chronic form of sleeping sickness, whereas in eastern and southern Africa, T. b. rhodesiense causes an acute form of the disease. HAT occurs in two stages: Stage 1 (early haemolymphatic) is characterised by non-specific clinical symptoms, such as malaise, headache, fever and peripheral oedema, whereas Stage 2 (late meningoencephalic) is characterised by neurological symptoms, including behavioural changes, severe sleeping disturbances and convulsions, which, if left untreated, lead to coma and death in 100% of cases. There are few current treatments for HAT and these are old, limited due to toxicity, diminishing in efficacy and can be complex to use. Treatment is stage-specific, and the only therapies available for Stage 2 are the more difficult to administer or more toxic drugs (3, 4) . There is a pressing need for new, safe and effective treatments for HAT, preferably oral drugs that can treat both stages.
There are many nitroheterocyclic compounds, including nitroimidazoles, which possess good oral therapeutic activity against protozoal parasites; however, concerns over toxicity and in particular genotoxicity has made drug development problematical. A typical anti-trypanosomal nitroimidazole is megazol (5) but its development was abandoned because of genotoxicity in bacteria and in mammalian systems with the resulting concerns about carcinogenicity (6) . Another example is metronidazole (7) , which is widely used as an antibiotic and antiprotozoal treatment. While the potential risks posed by the genotoxicity and carcinogenicity of metronidazole are still areas of active controversy (8) , the therapeutic usefulness of this compound, including the lack of evidence of clinical toxicity, despite widespread use, has kept the drug in the arsenal of key antimcicrobial drugs, included on the World Health Organisation (WHO) list of Essential Medicines (9) . Tinidazole, which is closely related to metronidazole, is used for the treatment of a variety of parasitic and bacterial infections (10) . Nifurtimox and benznidazole used for the treatment of Chagas disease, also caused by a trypanosome (11) , are further members of the class. These compounds possess both bacterial and mammalian cell genotoxicity (12, 13) and thus generate concern in terms of adverse long-term health effects (14) . However, when no safer alternative therapeutic options are available, the medical benefit of treating patients with these drugs is considered to outweigh their risks.
Compounds containing nitro groups are known to be activated by various enzymes, including nitroreductases, to form reactive radicals. This bioreduction requires low redox electron transfer systems. In general, the single-electron reduction potential of nitroimidazoles lies outside the normal range of mammalian redox systems (15) . However, if a oneelectron reduction of these compounds does occur, this can lead to the formation of a hydroxylamine intermediate, an unstable nitro radical anion that can go on to form a nitrite anion and an imidazole radical or be further reduced by accepting a second electron (16) . In the presence of oxygen, this can lead to the generation of a superoxide radical and then on to the formation of highly genotoxic nitroso derivatives (17) . Most of these reactive chemical species have the potential to interact with DNA.
The bacterial mutagenicity of many members of this group of compounds (often in both base-substitution strains such as TA100 and in frameshift-detecting strains such as TA98) has been known for many years (18) . Nitroreduction is essential for the expression of this mutagenicity, as shown for example in tests of the anti-schistosomal drug niridazole, such that activity is reduced 10-fold in nitroreductase-deficient TA100 and TA98 Salmonella strains compared to their nitroreductase-proficient counterparts. In addition, the desnitro analogue is not mutagenic (19) . These results were confirmed by Speck et al. (20) who extended the findings to show niridazole is also mutagenic for TA102, which has an A-T mutational site in the target of his G gene compared to the G-T sites in the target genes for mutation in TA100 and TA98. Again, these authors showed that mutagenicity is attenuated in a TA102 strain with a nitroreductase deficiency.
In view of the notable oral anti-infective or anti-parasitic activities observed in this class of compounds, there have been many attempts to separate the anti-parasitic activity, of relevant nitroheterocyclic compounds, from genotoxicity, with varying degrees of success (21) (22) (23) (24) . The difficulty remains that the antiparasitic mode of action of these compounds is to produce genotoxic compounds as a result of nitroreduction within the parasite, with subsequent lethal effects on the parasite. In a study on the resistance of trypanosomes to nifurtimox and benznidazole, it was shown that both drugs are activated by an nicotinamide adenine dinucleotide reduced-dependent, mitochondrially located, bacterial-like type 1 nitroreductase. Resistance appears to be due to downregulation of this enzyme. Loss of a single copy of this gene is sufficient to cause crossresistance to a wide variety of nitroheterocyclic compounds (25, 26) .
Thus, bacteria and parasites including trypanosomes possess low redox electron transfer systems capable of carrying out the nitroreduction and generating toxic compounds. The promise and the challenge were to find a compound that can be efficiently nitroreduced by the target parasites but not by equivalent mammalian enzymes.
Several new nitroimidazole drug candidates have emerged recently, of which PA-824 (27) and OPC-67683 (28) are currently in clinical development for the treatment of tuberculosis. Published data have indicated that neither of these compounds appears to possess genotoxicity, including in the Ames test, showing that it is possible and feasible to synthesise nitroimidazoles devoid of mutagenicity. This paper describes a genotoxicity evaluation of fexinidazole (1H-imidazole,1-methyl-2-[[4-methylthio) phenoxy] methyl] 5-nitroimidazole), a 2-substituted 5-nitroimidazole, rediscovered by the Drugs for Neglected Diseases initiative (DNDi) after extensive compound mining of drug companies and published databases. It was first synthesised by Hoechst and described in 1978 (29) . It was shown to possess potent in vitro and in vivo activity against trichomonads, Entamoeba histolytica, Trypanosoma cruzi and Trypanosoma brucei infections in mice (30) . The principal metabolites, sulfoxide and sulfone derivatives, were shown to have equivalent anti-parasitic activity to the parent molecule (31) . However, the development of this drug candidate was not pursued by Hoechst beyond preclinical studies. A detailed reassessment of the pharmacological and toxicological profile of fexinidazole, according to the current state of the art, has validated the compound as a promising drug candidate for HAT (32) , and Phase I clinical studies are currently ongoing.
Materials and methods
All studies described in this paper were carried under good laboratory practice (GLP) regulations, except where indicated.
Test compounds
Fexinidazole, 1H-imidazole,1-methyl-2-[[4-methylthio)phenoxy] methyl] 5-nitroimidazole, was manufactured for DNDi by Centipharm Ltd, Grasse, France, under current good manufacturing practice (cGMP) conditions and had a purity of .99.0%. Fexinidazole sulfone, 1-methyl-2-(4-methylsulfonyl phenoxymethyl)-5-nitroimidazole was manufactured by Centipharm Ltd and had a nominal purity of 99.9%. The structures of these compounds are shown in Figure 1 .
Positive control compounds used were as follows: Ames tests: 2-nitrofluorene (2NF), sodium azide, 4-nitroquinoline 1-oxide (4NQO), metronidazole (MTZ), 9-aminoacridine (9-AC), mitomycin C (MMC), benzo(a)pyrene (B(a)P), 2-aminoanthracene(2-AA) and nitrofurantoin (NFu).
In vitro micronucleus test: 4NQO, cyclophosphamide and vinblastine.
In vivo bone marrow micronucleus test in the mouse: cyclophosphamide. Ex vivo unscheduled DNA synthesis (UDS) study in the rat: 2-acetamidofluorene and dimethylnitrosamine.
All positive control compounds were of high grade and obtained from Sigma-Aldrich Chemical Company, Poole, Dorset, UK.
Drug preparation
Fexinidazole and the sulfone metabolite were prepared for in vitro studies as stock solutions in dimethyl sulphoxide (DMSO), further diluted with water or 0.5% methylcellulose in water to appropriate concentration required for the assays. For in vivo studies, fexinidazole was prepared as an optimised suspension comprising 5% w/v Tween 80/0.5% w/v Methocel in water.
Test systems Salmonella typhimurium strains TA98, TA100, TA1535 and TA1537 were originally obtained from the UK NCTC. Strain TA102 was derived from a culture obtained from GlaxoSmithKline Limited. Strain TA98NR was derived from a culture obtained from the University of York Cancer Research Unit and TA100NR was derived from a culture obtained from Novartis Pharma AG, Switzerland. Strains TA1535NR, YG7167 YG7168 and YG7127 were obtained from the National Institute of Health Sciences (NIHS), Japan. Strains TA98NR, TA100NR and TA1535NR are variants of strain TA98, TA100 and TA1535, respectively, that are deficient in 'classical' nitroreductase activity. Strain YG7127 is a further variant of strain TA1535 that has the classical nitroreductase gene deleted. Similarly, strainsYG7167 and YG7168 are variants of the strains TA1537 and TA102, respectively, with the classical nitroreductase gene deleted. These latter strains were specifically constructed for this study by targeted disruption of the cnr gene (classical nitroreductase) using techniques published previously (33) .
Young adult male Crl:CD-1 (ICR) mice were used for the bone marrow micronucleus test and young male Sprague-Dawley rats for the ex vivo liver UDS test.
Bacterial mutation assays (Ames test)
When the Salmonella typhimurium TA strains were first constructed by Bruce Ames and colleagues, uvrB mutants were selected, removing the main DNA excision repair pathway, by scoring cultures for chlorate resistance. The gene conferring chlorate resistance is in close proximity to the uvrB gene; thus, those cells acquiring chlorate resistance as a result of a deletion were likely to also have lost the uvrB gene as well. As each strain was selected independently, the commonly used Salmonella strains used in the Ames test have differently sized deletions. Thus, 47 genes are missing in TA100, 87 in TA1537 and 119 in TA98. Importantly, for this work, a major supplementary nitroreductase is absent in TA98 (and also in TA1535) as a result of these deletions (34) . Thus, for TA98NR and TA1535NR, these strains lack the two important nitroreductases for Salmonella, while the other NR strains used only lack the classical nitroreductase.
To evaluate bacterial mutagenicity, full Ames tests were carried out on fexinidazole and fexinidazole sulfone using the five strains of Salmonella typhimurium recommended by the relevant International Conference for Harmonisation (ICH) regulatory guideline, as well as the corresponding nitroreductase-deficient strains, as above. Standard bacterial plate incorporation assays were carried out, essentially as described by Maron and Ames (35) .
Tests on fexinidazole were carried out with and without rat liver postmitochondrial fraction plus co-factors (S9 mix) to provide a mammalian metabolic activation system. The S9 fraction was prepared from SpragueDawley rats pretreated with the mixed cytochrome P 450 enzyme inducer Aroclor 1254. A total of 0.5 ml of S9 mix containing 10% S9 fraction was added to 2.5 ml agar overlays.
Tests on fexinidazole sulfone were carried out only in the absence of rat liver S9 (as this is a metabolite). After incubation at 37°C for 3 days, plates were scored for mutant colonies using a Seescan Colony Counter (Seescan plc).
In vitro micronucleus tests using human lymphocytes Duplicate human lymphocyte cultures were prepared from the pooled blood of two donors in two independent experiments as defined in the OECD Guideline 487 (36) . For fexinidazole, treatments covering a broad range of concentrations, separated by narrow intervals, were carried both in the absence and in the presence of metabolic activation rat liver (S9). The final concentration of S9 fraction in the media used for this test was 2%.
The highest concentration of fexinidazole tested was 220 lg/ml. Cells were treated with the drug 24 and 48 h following stimulation by the mitogen phytohaemagglutinin (PHA). In the absence of S9, the exposure period was 20 h plus a 28-h expression period (�S9) or for 3 h with a 45-h expression period (þS9). The test concentrations for analyses of micronuclei were selected by evaluating the effect of fexinidazole on the replication index. In each experiment, micronuclei were analysed at three concentrations. The highest concentrations tested were limited by precipitation observed at the end of the treatment period.
Similar tests were carried out on fexinidazole sulfone. As per the Ames test, this was carried out in the absence of rat liver S9 only. In this case, the cells were treated 48 h after mitogen stimulation with PHA and as there were no tests in the presence of S9, an extended exposure period was included (24 h, no expression time).
Mouse bone marrow micronucleus test Groups of six Crl:CD-1 (ICR) male mice were treated with fexinidazole using two oral doses of 0 (vehicle control), 500, 1000 or 2000 mg/kg given 24 h apart, and bone marrows were harvested 24 h after the second dose (37) . Slides of bone marrow cells were prepared, Giemsa stained and 2000 polychromatic erythrocytes per animal were scored for micronuclei. The percentage of polychromatic erythrocytes of the total of erythrocytes in each bone marrow sample was used to estimate toxicity.
Ex vivo UDS test in rat liver
The standard autoradiographic method was used (38) . Groups four male Sprague-Dawley Crl:CDd (SD) rats received fexinidazole doses of 500, 1000 or 2000 mg/kg orally (two groups per dose), and the livers were sampled either 2-4 h or 12-14 h after test compound administration. Hepatocyte suspensions were prepared and incubated in the presence of tritiated thymidine. Slides of fixed hepatocytes were coated in photographic emulsion and stored for 14 days at 4°C in the dark. The silver grains that accumulated in the emulsion due to radioactive decay of the tritium were counted above both the nuclei and equivalent areas of cytoplasm. Grain counting was performed using a microscope with a video camera connected to an image analysis system (Perceptive Instruments) and a computer programmed for automatic data capture. A total of 100 cells were analysed per animal (50 from each of two slides). The extent of DNA repair was estimated by calculating the mean of the difference between the nuclear and cytoplasmic counts (nuclear net grain count) per sample.
All genotoxicology studies in animals were carried out by Covance Laboratories Ltd, Harrogate, England, according to their internal Standard Operating Procedures, the applicable ICH guidelines (ICH S2A Toxicokinetic measurements Blood samples were taken from satellite animals from the bone marrow micronucleus study and from the UDS study, 1 h after dosing with 2000 mg/kg in each case. This is close to the Tmax for fexinidazole. Concentrations of fexinidazole and its two major metabolites were determined in plasma from these samples by a liquid chromatography-mass spectroscopy-mass-spectroscopy (LC-MS-MS) method following plasma protein precipitation in a 96-well plate format.
These analyses were carried out by The Bioanalysis and Analytical Control Department, Neviano Medical Sciences, Accelera, Milan Italy. A preliminary study using the same methodology had also been carried out at CIT, Evreux, France, but in this study, samples were taken 4 h after dosing.
Metabolism of fexinidazole using Aroclor 1254-induced rat liver S9 fraction
Fexinidazole was incubated at a single nominal concentration of 200 lg/ml with Aroclor 1254-induced rat liver S9 (1 mg/ml) at 37°C for 0, 15 and 60 min. Additional incubations were conducted with fexinidazole at a nominal concentration of 200 lg/ml for 0, 2, 3 and 6 h. Aroclor 1254-induced rat liver S9 and [ 14 C]fexinidazole in Tris-HCl buffer, pH 7.4, were warmed to �37°C for �5 min before initiation of the reaction by the addition of nicotinamide adenine dinucleotide phosphate reduced (2 mM). The total incubation volume was 0.2 ml. All reactions were terminated by the addition of 0.1 ml acetonitrile. Incubations were also conducted in the absence of rat liver S9. All test incubations were conducted in triplicate. Following centrifugation (15 300g, 5 min), protein-free supernatants were transferred to clean vials and stored frozen prior to analysis or injected directly onto the high performance liquid chromatography system. Recovery of radioactivity from each incubation mixture was measured by liquid scintillation counting. Chromatographic data were captured online using a validated data acquisition system (Laura 3.4.7; LabLogic Systems Ltd). All other calculations were carried out using Excel 2003.
Nitroreductase measurements of selected Ames strains
Two new nitroreductase-deficient strains, TA1537NR (YG7167) and TA102NR (YG7168), were kindly constructed for this project by Dr Y. Yamada from the National Institute of Health Sciences Tokyo by disrupting the gene for the supplementary nitroreductase, nsfB, using a procedure reported previously (33) . To confirm that the procedure had been successful, nitroreductase measurements were made of extracts from these strains, their nitroreductase parental strains and also the strain TA98NR. The procedure used to quantify nitroreductase enzymatic activity was carried out at the University of Swansea under contract and were not carried out under GLP conditions. The nitroreductase activities of cell-free extracts from the selected strains were estimated by the decrease in absorbance at 373 nm resulting from the reduction of the nitrofurantoin substrate (39) . Each strain was tested in parallel and the whole procedure repeated on different days up to five times.
Redox potential measurement
One-electron reduction potentials were determined by fast kinetic spectrophotometry (pulse radiolysis) in aqueous solutions using an established procedure (non-GLP) (40) .
Results

Nitroreductase activities of selected strains
The nitroreductase activities of TA102/TA102NR (YG7168), TA1537/TA1537NR (YG7167) and TA98NR are shown in Figure 2 . The data support the selection of the new NR strains through the disruption of the nsfB gene as being truly nitroreductase deficient. The remaining nitroreductase activity seen in TA1537NR and TA102NR is presumably due at least in part to the activity of the 'classical nitroreductase gene (cnr)'. It was surprising to see low levels of nitroreductase activity remaining in TA98NR, which has lost the activity of both nsfB and cnr genes, which suggests that there is a third nitroreductase gene active in these cells. Although TA100 is not included in these assay of nitroreductase activity, it is known that it retains at least one functional nitroreductase (34) and as shown in its sister strains.
In vitro metabolism of fexinidazole In vivo studies had shown that fexinidazole is rapidly metabolised to form the sulfoxide and the sulfone (see Table  VII from the toxicokinetic studies carried out to support the in vivo genotoxicity tests); thus, the exposure is mainly to these two metabolites. To ascertain that these two metabolites are formed under the conditions of the in vitro genotoxicity studies, in vitro metabolism was studied using rat liver S9. The results show that the sulfoxide is formed rapidly and efficiently under these conditions, but only trace amounts of the sulfone are found (Figure 3) . Therefore, the sulfone was synthesised and tested separately, in addition to the parent molecule.
Ames tests of fexinidazole
Fexinidazole was tested in the five standard Salmonella strains as required by the ICH guideline for genotoxicity testing for pharmaceutical registration. In addition, to determine the contribution of bacterial nitroreductase enzymes to mutagenicity, the compound was also tested in the corresponding strains deficient in one or two nitroreductases. A summary of the results is shown in Table I . Figures 4-7 show the results for TA98 and TA100 plus their nitroreductase-deficient counterparts, with (Figures 4 and 5) and without ( Figures 6 and 7-9 ) metabolic activation (S9). Mutagenicity was observed in all strains to different degrees, except in TA1537 where the original weak positive response was not reproducible. In each case, mutagenicity was either lost (e.g. TA98NR versus TA98) Strains possessing active major nitroreductase (NR) genes-TA100, TA1537 and TA102 ; strains lacking an active classical NR gene-TA100NR; YG7127 (TA1535 derivative), YG7167 (TA1537 derivative) and YG7168 (TA102 derivative); strain lacking an active supplementary NR gene (TA98) and strains lacking both major NR genes-TA98NR and TA1535NR. Fig. 4 . Ames tests of fexinidazole using strains TA98 and TA98NR (absence of S9).
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or significantly attenuated (e.g. TA100NR versus TA100) in the strains deficient in nitroreductase compared to their nitoreductase-proficient counterpart. In the strains lacking both the classical nitroreductase and the supplementary nitroreductase, i.e.TA98NR and TA1535NR, mutagenicity was all but abolished, suggesting that the residual mutagenicity seen in the other strains was due to the activity of the supplementary nitroreductase. These data suggest that the positive mutagenicity signal observed for fexinidazole in the Ames test is due to a reduction of fexinidazole by either or both bacterial nitroreductases.
In most cases where mutagenicity was observed, potency of the signal was increased in the presence of rat liver S9. As fexinidazole is rapidly metabolised to its sulfoxide by rat liver S9 (Figure 2 ), this suggests that this metabolite is a more active bacterial mutagen than fexinidazole itself. In the absence of rat liver S9, no activity was observed in TA102. However, activity was observed in this strain in the presence of S9. These data suggest that the sulfoxide possesses additional mutagenic activity for this strain. However, again, activity was attenuated in the nitroreductase-deficient derivative showing that nitroreduction plays a part in the mutagenicity observed.
Ames tests of fexinidazole sulfone
As only trace amounts of fexinidazole sulfone are formed by incubation of fexinidazole with rat liver S9, this metabolite was tested in its own right. As this compound is a metabolite, tests were carried out in the absence of rat liver S9 only. The results shown in Table II and Figures 8 and 9 for TA98 and TA100 (plus their nitroreductase-deficient counterparts) demonstrate a broadly similar result to fexinidazole, with mutagenic activity lost or attenuated in the strains deficient in nitroreductase activity.
In vitro micronucleus tests of fexinidazole and fexinidazole sulfone Both fexinidazole and fexinidazole sulfone were subsequently tested in in vitro micronucleus tests using human peripheral lymphocytes. As it was shown that fexinidazole is metabolised to its sulfoxide under the conditions of the assay, the results shown in Table IIIa and b cover fexinidazole and fexinidazole sulfoxide. The results for fexinidazole sulfone are shown in Table IV . Neither compound induces chromosome damage in human lymphocytes under the conditions of these assays. Thus, the mutagenic potential seen in the bacterial Ames test is not realised in these mammalian cells in vitro. Strains possessing active major nitroreductase (NR) genes-TA100, TA1537 and TA102; strains lacking an active classical NR gene-TA100NR; YG7167 (TA1537 derivative) and YG7168 (TA102 derivative); strain lacking an active supplementary NR gene (TA98) and strains lacking both major NR genes-TA98NR and TA1535NR.
Genotoxicity profile of fexinidazole
In vivo mouse bone marrow micronucleus test Fexinidazole was subsequently tested in an in vivo bone marrow micronucleus test. As shown in Table V , even when given at doses up to the maximum recognised by international guidelines, fexinidazole does not induce chromosomal damage in this assay, confirming the lack of activity seen in the in vitro micronucleus study. A preliminary study had also been carried out at the CIT Laboratories in France with the same outcome (data not shown). The exposure to fexinidazole and the sulfoxide and sulfone metabolites in these assays was confirmed by HPLC analysis (Table VIIa) .
Ex vivo UDS test
The rationale for choosing the ex vivo UDS test as the second in vivo test was as follows:
1. Previous studies carried out by Bayer had shown that UDS was detected at low doses in three of five tests of fexinidazole using A549 cells in vitro. Thus, there was a wish to explore this endpoint in an in vivo test. 2. Fexinidazole is relatively non-toxic in rat studies given high doses for 28 days (32). The only target organ in the rat is the liver where increased liver weight and hypertrophy of centrilobular hepatocytes were seen. 3. The liver is the site of primary metabolism of fexinidazole, so the cells in this organ are exposed to the highest concentrations of the major metabolites. It is also likely that the liver is also exposed to high concentrations of the parent fexinidazole as it is rapidly metabolised by the liver, reducing systemic exposure, as per the toxicokinetic profile in this paper and from separate drug metabolism pharmacokinetic studies (32). 4. Some nitro goup containing aromatic compounds have been shown to induce UDS in hepatocytes in vitro and in vivo (41,42).
As shown in Table VI , there was no indication of any UDS at any dose at either time point. The exposure to fexinidazole and the sulfoxide and sulfone metabolites in this study was confirmed by HPLC analysis (Table VIIb) .
Redox potential studies
It is known that the nitroreductase enzymes in bacteria can nitroreduce compounds at low redox potentials, whereas equivalent mammalian enzymes cannot, under normal conditions. Fexinidazole, the sulfoxide and the sulfone were shown to have low single-electron redox potentials being À511, À493 and À488 mV, respectively. The same parameter for metronidazole was À516 mV and megazol was significantly less negative at À422 mV.
Discussion
Substituted nitroimidazoles are widely used as antimicrobials and anti-parasitic compounds, but there are persistent concerns about genetic toxicity and potential carcinogenicity of the drugs in present use. There is a pressing need for an effective, safe and easy to administer therapy for African sleeping sickness (HAT). Fexinidazole, a 5-nitroimidazole dropped from drug development by Hoechst in the 1980's, was rediscovered by DNDi as a potential new treatment for HAT. The potent anti-trypanosomal activity of fexinidazole was confirmed in acute mouse models, including being able to cure a stringent model of second stage HAT and the chronic mouse model involving brain infection (32) . As part of the efforts to develop this compound for possible therapeutic use, a full toxicology battery was completed, including a full assessment of genotoxicity.
Because fexinidazole is rapidly metabolised in vivo to sulfoxide and sulfone metabolites, the studies were designed to include the assessment of both metabolites. Metabolism studies in vitro showed that the sulfoxide metabolite is formed efficiently by rat liver S9 in the conditions of the in vitro genotoxicity assays, but only traces of the sulfone metabolite were detected. Therefore, the in vitro genotoxicity studies (Ames and in vitro micronucleus test) were repeated with this compound. For the in vivo studies, the adequate exposure to all three compounds was confirmed by measuring the plasma levels in satellite animals.
As expected, mutagenic activity was observed for fexinidazole and its metabolites in the Ames test. However, this activity was attenuated or lost in Ames strains lacking one or more of the nitroreductases normally present in the Salmonella cells. It is known that bacterial nitroreductases can reduce nitrocontaining compounds of low redox potentials, whereas the mammalian counterparts cannot. This nitroreduction results in the formation of reactive chemical species with potential to Fig. 9 . Ames tests of sulfone metabolite using strains TA100 and TA100NR (absence of S9). react with DNA and thus cause genetic damage. The observation that the mutagenic activity is attenuated or lost in Salmonella strains deficient in nitroreductases suggests that mutagenicity is not an intrinsic property of these compounds but the result of activation by bacteria-specific nitroreductases.
When tested in the in vitro micronucleus test on human lymphocytes, the in vivo bone marrow micronucleus test and the ex vivo UDS test rat liver cells, no mutagenic activity was seen for fexinidazole and its sulfoxide and sulfone metabolites. Toxicokinetic studies demonstrated significant exposure to all the three compounds in the plasma of the treated animals and thus, the bone marrow and the liver were used as targets for genotoxicity evaluations. This combination of tests meets the ICH (S2B) genotoxicity testing requirements for registration of new pharmaceuticals.
Redox measurements showed that fexinidazole and its sulfoxide and sulfone metabolites possess highly negative single-electron redox potentials of �511, �493 and �488 mV, respectively. This is consistent with the absence of mutagenic activity in mammalian cells as mammalian nitroreductases are expected to be incapable of nitro-reducing compounds with such negative single-electron redox potentials.
The potential of nitrogroup containing compounds to cause mutagenic damage to intestinal cells following nitroreduction by bacteria in the intestinal flora, with possible diffusion of reduced metabolites has been contested in the literature for more than 30 years (review 43). However, this is deemed unlikely to be significant due to the short half-life of reduced intermediates of 5-nitroimidazoles and the failure to detect nitroreduced metabolites of compounds like metronidazole in the intestine of human patients (44) . This issue was considered by the Scientific Committee for Animal Nutrition (SCAN) of the European Commission for the 5-nitroimidazole dimetrinidazole (metronidazole was also discussed). Dimetrinidazole The vehicle was DMSO. b The highest concentrations selected were selected on toxicity, precipitation or a maximum of 500 lg/ml. The positive controls were 5-nitroquinoline-N-oxide (5NQO) -S9 and cyclophosphamide (CPA) þS9.
Genotoxicity profile of fexinidazole has a similar genotoxicity profile to fexinidazole. The SCAN committee noted that 'when the production within intestinal flora of DMZ reactive metabolites is concerned, it must be noted that the lifetime of these metabolites depends on the reduction potential of the parent molecule the lower the potential the longer is the half-life ($12 sec for 5-nitroimidazoles) and the more limited is the damage (45) . The absence in long-term studies with 5-nitroimidazole compounds of intestinal tumours is consistent with these observations (46) . In support of this, latter statement for the related nitro-containing compounds (all of whom induce mutations in the Ames test due to bacterial nitroreduction), metronidazole (47, 48) , benznidazole (49) and nifurtimox (50) have all been tested for carcinogenicity in rodents and none have produced intestinal tumours. In further support of the lack of proven hazard to intestinal cells for nitrocontaining compounds, a study of AMP397, a compound with this chemical substructure (see Figure 10) proposed for use as an anti-epilectic, addressed the issue of possible gut bacteria generated genotoxins due to nitroreduction (51) . AMP397 has a very similar profile to fexinidazole in genotoxicity tests: mutagenic activity was observed in the standard Ames test strains but loss of that activity in their nitroreductase-deficient counterparts and negative results in the chosen mammalian cell assays. A mutagenicity study was carried out in vivo in the MutaMouse model, in which the test animals were given five daily treatments of AMP397 at the maximum tolerated dose. Samples were taken at 3, 7 and 31 days after treatment. No evidence of mutagenicity was seen in the colon or liver. Similarly, an in vivo comet assay in the rat (measuring DNA strand breakage) did not detect any genetic damage in the jejunum or liver of treated animals after dosing the animals at a dose six times higher than that possible in the MutaMouse study. A radioactive DNA-binding study of AMP397 also failed to show any DNA binding in rat liver. Thus, if a mutagenic metabolite was formed by intestinal bacteria, it was unable to induce genetic damage in local intestinal tissue. In summary, there is no evidence to prove that 5-nitroimidazoles (and compounds with related nitro-containing substructures) pose a genotoxic or carcinogenic risk to intestinal cells, whereas there is significant evidence that supports a lack of risk from this theoretical pathway. It is legitimate to consider 5-nitroimidazoles as a class with similar biological properties; thus, there is no compelling reason to regard fexinidazole as separate to the examples given above. However, to provide additional weight of evidence as to its lack of genotoxicity, an additional in vivo assay measuring effects on cells of the GI tract (e.g. a Comet assay) would be of value.
Taken together, these studies show that fexinidazole is unlikely to pose a genotoxic hazard for patients. In terms of human hazard assessment, it is important to recognise that any treatment of patients with fexinidazole will be short-term (7-14 days), multiple treatments are unlikely, HAT is 100% lethal if untreated, most existing treatments are either highly toxic and are becoming increasingly ineffective due to resistance of the parasite. Fexinidazole has received regulatory approval for the conduct of studies in humans from the French regulatory authorities (AFSSAPS) and is undergoing clinical trials (http:// clinicaltrials.gov/ct2/show/NCT00982904). There are further nitroimidazoles under investigation for possible development for use in treating HAT and Chagas disease that are being selected on the basis of high efficacy and low genotoxic potential (52) .
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